Skip to main content

Table 1 Association between the clinicopathological features of CRC patients stratified by POLE mutation, MSI, and MLH1 methylation status

From: Clinical and epigenetic features of colorectal cancer patients with somatic POLE proofreading mutations

Characteristics POLE (n = 4) MSI-M (n = 29) MSI-U (n = 36) non-MSI (n = 944) P value
Age Mean (range) 52.5 (41–63) 76.9 (60–89) 59.5 (24–87) 66.0 (21–95)  < .0001
   > 70 0 (0) 22 (75.9) 7 (19.4) 365 (38.7)  < .0001
  55–69 2 (50%) 7 (24.1) 18 (50.0) 441 (46.7)  
  40–54 2 (50%) 0 (0) 7 (19.4) 118 (12.5)  
   < 39 0 (0) 0 (0) 4 (11.1) 20 (2.1)  
Gender Female 2 (50%) 19 (65.5%) 13 (36.1%) 389 (41.2%) 0.0593
  Male 2 (50%) 10 (34.5%) 23 (63.9%) 555 (58.8%)  
Tumour location Right 4 (100%) 27 (93.1%) 13 (36.1%) 282 (29.9%)  < .0001
  Left 0 (0) 2 (6.9%) 23 (63.9%) 662 (70.1%)  
Histology Well 0 (0) 7 (24.1%) 6 (16.7%) 276 (29.2%)  < .0001
  Moderate 3 (75%) 7 (24.1%) 20 (55.6%) 571 (60.5%)  
  Poor/muc 1 (25%) 15 (51.7%) 10 (27.8%) 97 (10.3%)  
UICC stage I 1 (25%) 11 (37.9%) 14 (38.9%) 197 (20.9%) 0.0011
  II 3 (75%) 10 (34.5%) 14 (38.9%) 246 (26.1%)  < .0001*
  III 0 (0) 6 (20.7%) 4 (11.1%) 297 (31.5%)  
  IV 0 (0) 2 (6.9%) 4 (11.1%) 204 (21.6%)  
RAS mutational status BRAF mutation 0 (0) 20 (69.0%) 4 (11.1%) 35 (3.7%)  < .0001
  KRAS mutation 0 (0) 0 (0) 8 (22.2%) 307 (32.5%)  
  Wild-type 4 (100%) 9 (31.0%) 24 (66.7%) 602 (63.8%)  
Methylation score Mean (range) 2 (2) 3.2 (2–4) 1.9 (0–4) 1.9 (0–4)  < .0001
MGMT methylation Extensive 0 (0) 17 (58.6%) 4 (11.1%) 166 (17.6%)  < .0001
  Partial 0 (0) 1 (3.5%) 5 (13.9%) 60 (6.4%)  
  Unmethylation 4 (100%) 11 (37.9%) 27 (75.0%) 718 (76.1%)  
SFRP2 methylation Extensive 4 (100%) 28 (96.6%) 23 (63.9%) 602 (63.8%) 0.0158
  Partial 0 (0) 1 (3.5%) 8 (22.2%) 194 (20.6%)  
  Unmethylation 0 (0) 0 (0) 5 (13.9%) 148 (15.7%)  
  1. P-values were calculated using the Chi-squared test
  2. * P-value was calculated between stages I–II and III–IV